{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:54:12Z","timestamp":1781754852321,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01793-z","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T04:19:16Z","timestamp":1779596356000},"page":"3461-3477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03569293","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03607422","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"Kilian","family":"Eyerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-920X","authenticated-orcid":false,"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1415","authenticated-orcid":false,"given":"Gregor","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9037-121X","authenticated-orcid":false,"given":"Vipul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-2482","authenticated-orcid":false,"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-4234","authenticated-orcid":false,"given":"Paula C.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6455-4825","authenticated-orcid":false,"given":"Pablo Coto","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4161-1467","authenticated-orcid":false,"given":"Michael","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0584","authenticated-orcid":false,"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-9286","authenticated-orcid":false,"given":"Alvaro","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"1793_CR1","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et\u00a0al. ETFAD\/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1793_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et\u00a0al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89:519\u201328.","journal-title":"J Am Acad Dermatol"},{"key":"1793_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Bunick CG, Hong HC, et\u00a0al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2025;192:36\u201345.","journal-title":"Br J Dermatol"},{"key":"1793_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et\u00a0al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1793_CR5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/exd.14368","volume":"30","author":"S Ribero","year":"2021","unstructured":"Ribero S, Puglisi B, Giura MT, et\u00a0al. Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients. Exp Dermatol. 2021;30:1717\u20138.","journal-title":"Exp Dermatol"},{"key":"1793_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, et\u00a0al. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23:575\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"1793_CR7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/ced\/llad040","volume":"48","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Antonelli F, et\u00a0al. Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment. Clin Exp Dermatol. 2023;48:558\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"1793_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/DER.0000000000000590","volume":"31","author":"J Jaros","year":"2020","unstructured":"Jaros J, Hendricks AJ, Shi VY, et\u00a0al. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31:169\u201377.","journal-title":"Dermatitis"},{"key":"1793_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et\u00a0al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37:1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1793_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40629-025-00340-0","volume":"34","author":"S Royeck","year":"2025","unstructured":"Royeck S. Biologics in the treatment of atopic dermatitis: approved active substances and monoclonal antibodies in advanced clinical trials. Allergo J Int. 2025;34:159\u201366.","journal-title":"Allergo J Int"},{"key":"1793_CR11","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, et\u00a0al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15:2839.","journal-title":"Nat Commun"},{"key":"1793_CR12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, et\u00a0al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155:1312\u20135.","journal-title":"JAMA Dermatol"},{"key":"1793_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, et\u00a0al. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84:1339\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"1793_CR14","unstructured":"RINVOQ (upadacitinib). Prescribing information. AbbVie Inc.; 2025. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 28 July 2025."},{"key":"1793_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et\u00a0al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"1793_CR16","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et\u00a0al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368.","journal-title":"Lancet"},{"key":"1793_CR17","first-page":"10","volume":"241","author":"JP Thyssen","year":"2025","unstructured":"Thyssen JP, Rosmarin D, Costanzo A, et\u00a0al. Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the Heads Up study. Dermatology. 2025;241:10\u20138.","journal-title":"Dermatology"},{"key":"1793_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et\u00a0al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83:839\u201346.","journal-title":"J Am Acad Dermatol"},{"key":"1793_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, et\u00a0al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172:1353\u20137.","journal-title":"Br J Dermatol"},{"key":"1793_CR20","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et\u00a0al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38:2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1793_CR21","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/jdv.18995","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, de Bruin-Weller MS, Deleuran M, et\u00a0al. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: integrated analysis of three upadacitinib phase 3 trials. J Eur Acad Dermatol Venereol. 2023;37:1634\u201341.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1793_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad162.026","volume":"188","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Gooderham MJ, Katoh N, et\u00a0al. Achievement of minimal disease activity is associated with improvements in symptoms, quality of life and treatment satisfaction in patients with atopic dermatitis. Br J Dermatol. 2023;188:ljad162.026 (403).","journal-title":"Br J Dermatol"},{"key":"1793_CR23","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","volume":"13","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Hong HC, Calimlim BM, et\u00a0al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol Ther. 2023;13:2247\u201364.","journal-title":"Dermatol Ther"},{"key":"1793_CR24","doi-asserted-by":"publisher","first-page":"2509541","DOI":"10.1080\/09546634.2025.2509541","volume":"36","author":"E Mortato","year":"2025","unstructured":"Mortato E, Gori N, Caldarola G, et\u00a0al. Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? J Dermatolog Treat. 2025;36:2509541.","journal-title":"J Dermatolog Treat"},{"key":"1793_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/ijd.ijd_931_23","volume":"69","author":"SY Park","year":"2024","unstructured":"Park SY, Hong N, Kook HD, et\u00a0al. Successful treatment with upadacitinib of patient with persistent head and neck atopic dermatitis refractory to dupilumab: a case report. Indian J Dermatol. 2024;69:203.","journal-title":"Indian J Dermatol"},{"key":"1793_CR26","doi-asserted-by":"publisher","first-page":"2242540","DOI":"10.1080\/09546634.2023.2242540","volume":"34","author":"Y Yang","year":"2023","unstructured":"Yang Y, Chen J, Yu N, et\u00a0al. Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab. J Dermatol Treat. 2023;34:2242540.","journal-title":"J Dermatol Treat"},{"key":"1793_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et\u00a0al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157:1047\u201355.","journal-title":"JAMA Dermatol"},{"key":"1793_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","volume":"152","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Irvine AD, Brunner PM, et\u00a0al. The role of Janus kinase signaling in the pathology of atopic dermatitis. J Allergy Clin Immunol. 2023;152:1394\u2013404.","journal-title":"J Allergy Clin Immunol"},{"key":"1793_CR29","unstructured":"Guttman-Yassky E, Pavel AB, Silverberg JI, et\u00a0al. Upadacitinib treatment induces significant improvements in Th2 (eosinophil count, serum CCL17\/18\/26) and Th22 (IL-22) levels in atopic dermatitis that are associated with improvements in itch and clinical severity. Poster presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Congress; April 5, 2020: Chicago, Illinois."},{"key":"1793_CR30","doi-asserted-by":"crossref","unstructured":"Eyerich K, Kwatra SG, Bunick CG, et\u00a0al. Impact on multiple inflammatory axes drives a high level of efficacy to upadacitinib: biomarker analysis from LEVEL UP, a phase 3b\/4 head-to-head study with dupilumab. Poster presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025); March 7\u201311, 2025; Orlando, FL, USA","DOI":"10.1016\/j.jaad.2025.05.897"},{"key":"1793_CR31","unstructured":"D'Avino P, Kim J, Li M, et\u00a0al. Distinct roles of IL-4, IL-13, and IL-22 in human skin barrier dysfunction and atopic dermatitis. Allergy. 2025:1\u201318."},{"key":"1793_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111193","volume":"125","author":"L Li","year":"2023","unstructured":"Li L, Wu N, Liu T, et\u00a0al. The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients. Int Immunopharmacol. 2023;125:111193.","journal-title":"Int Immunopharmacol"},{"key":"1793_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","volume":"127","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Lei D, Ahmed A, et\u00a0al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127:83-90.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1793_CR34","doi-asserted-by":"crossref","unstructured":"Ansbro B, Silverberg JI. Not all itch is created equal in atopic dermatitis: a prospective observational study of the heterogeneous characteristics of itch. Dermatitis. 2025:derm20250082.","DOI":"10.1089\/derm.2025.0082"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01793-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:23:46Z","timestamp":1781753026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01793-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01793-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kilian Eyerich declares acting as a consultant and investigator for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, LEO Pharma, Lilly, Janssen, Incyte, Sitry, Sanofi, Novartis, and UCB. Pedro Mendes-Bastos has served as a speaker and\/or consultant for AbbVie, Almirall, Alumis, Apogee, CS Labs, Evelo Biosciences, Galderma, GlaxoSmithKline, Johnson & Johnson Innovative Medicine, LEO Pharma, Lilly, L\u2019Oreal, Novartis, Organon, Pfizer, Pierre Fabre, Regeneron, Sanofi, Takeda, and Viatris; and as a principal investigator in clinical trials supported by AbbVie, Alumis, Amgen, Biogen, Cantabria Labs, Johnson & Johnson Innovative Medicine, Pfizer, Novartis, Sanofi, and Sanofi-Regeneron. Gregor Holzer acts as a consultant, speaker, and\/or investigator for AbbVie, Almirall, Galderma, LEO Pharma, Lilly, and Sanofi. Vipul Jain has received honoraria for grants and\/or research funding for being a speaker, consultant, and\/or advisory board member for AbbVie, Amgen, ALK, Aralez, Arcutis, AstraZeneca, Bausch Health, CAIT, Celgene, Celltrion, Covis Pharma, Eczema Society of Canada, GSK, Incyte, LEO Pharma, Medexus, Mylan, Novartis, Pediapharm, Pfizer, Sanofi-Genzyme, Regeneron, and Takeda. He has participated as a primary investigator in clinical trials sponsored by Probity Medical Research Inc. and has been an investigator in clinical trials sponsored by AbbVie, Amgen, Allakos, Apollo Therapeutics, Arcutis, Astra Zeneca, Evommune, Galderma, GSK, Janssen, Johnson & Johnson, Kymab, LEO Pharma, Lilly, Organon, Novartis, Pfizer, Sanofi-Genzyme, and Triveni Bio. He is a director of Allergy Research Canada Inc. Norito Katoh has received honoraria as a speaker\/consultant for AbbVie, Celgene Japan, Jansen Pharma, Kyowa Kirin, LEO Pharma, Lilly Japan, Maruho, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Sanofi, Taiho Pharmaceutical, and Torii Pharmaceutical; and grants as an investigator from AbbVie, A2 Healthcare, Boehringer Ingelheim Japan, Eisai, Jansen Pharma, Kyowa Kirin, LEO Pharma, Lilly Japan, Maruho, Sun Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical. Paula C. Luna has received consulting fees, honoraria, or grant support or lecturing fees from AbbVie, Amgen, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, GSK, Janssen, La Roche Posay, Lilly, Novartis, Pfizer, Pierre Fabre Laboratory, Sanofi\u2011Genzyme, and Takeda. Pablo Coto Segura has received grants\/honoraria from and\/or has conducted clinical trials for AbbVie, Almirall, Amgen, LEO Pharma, Sanofi, and UCB. Michael Lane, Ayman Grada, and Alvaro Moreira are full-time employees of AbbVie, and may hold AbbVie stock or stock options. Christopher G. Bunick has served as an investigator and\/or consultant for AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, EPI Health\/Novan, Galderma, Incyte, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, UCB, and Veradermics. Christopher G. Bunick is an editorial board member of\n                      Dermatology and Therapy\n                      . Christopher G. Bunick was not involved in the\u00a0selection\u00a0of peer reviewers for the manuscript or any of the\u00a0subsequent\u00a0editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocols, informed consent forms, and recruitment materials were approved by Advarra (Columbia, MD, USA) and the independent ethics committee or institutional review board at each site before patient enrollment (Supplementary Table\n                      \n                      ). Studies were conducted in accordance with International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. Patients (or parents\/legal guardians of adolescent patients) provided written informed consent before screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}